ECHELON-1 Phase 3 trial

June 6, 2019

Adcetris Combo Continues to Show Better Results Than Chemotherapy Alone, Phase 3 Update Reveals

News

Seattle Genetics‘ Adcetris (brentuximab vedotin) in combination with standard chemotherapy continues to show better clinical activity than bleomycin plus standard chemotherapy, as a front-line treatment for patients with Hodgkin’s lymphoma, updated ... Read more

February 15, 2019

European Commission Approves Adcetris/Chemo Combo for Some Hodgkin’s

News

The European Commission has approved the used of Adcetris (brentuximab vedotin) in combination with standard chemotherapy for the initial treatment of advanced CD30-positive Hodgkin’s lymphoma patients in the European Union, Norway, Liechtenstein and Iceland. The approval, ... Read more

September 26, 2018

Adcetris, Chemo Combo Approved in Japan for Untreated, Advanced Hodgkin’s Lymphoma

News

The Japanese Ministry of Health, Labour and Welfare has approved the use of Adcetris (brentuximab vedotin) in combination with standard chemotherapy as a frontline treatment for CD30-positive Hodgkin’s lymphoma patients ... Read more

March 22, 2018

FDA Approves Adcetris, Chemotherapy Combo for Advanced Classical Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration approved the combination of Seattle Genetics’ Adcetris (brentuximab vedotin) with chemotherapy for the treatment of adults with previously untreated stage 3 or 4 classical Hodgkin’s ... Read more

February 1, 2018February 1, 2018

Adcetris-Chemo Combo Delays Disease Progression in Newly-diagnosed Advanced Lymphoma, Trial Shows

News

Results from a Phase 3 clinical trial show that adding Adcetris (brentuximab vedotin) to a chemotherapy regimen reduces the risk of disease progression, death, or use of additional anticancer therapies for ... Read more

January 23, 2018January 23, 2018

Adcetris Combo Effective as First-line Treatment for Hodgkin’s Lymphoma, Trial Results Show

News

Adcetris (brentuximab vedotin) in combination with chemotherapy is a valuable treatment option for patients with previously untreated advanced Hodgkin’s lymphoma, researchers said after revealing data from a Phase 3 clinical ... Read more

January 3, 2018

FDA to Review Adcetris, Chemo Combo as First-line Treatment for Advanced Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has agreed to review Adcetris (brentuximab vedotin) in combination with chemotherapy as a frontline treatment for patients with advanced Hodgkin’s lymphoma, according to Seattle Genetics. The supplemental Biologics License ... Read more

November 16, 2017November 17, 2017

Takeda to Showcase Adcetris as First-line Therapy in Hodgkin’s Lymphoma at ASH Meeting

News

Takeda Pharmaceutical will present new data on Adcetris (brentuximab vedotin) as first-line therapy for advanced Hodgkin’s lymphoma at the 59th American Society of Hematology (ASH) Annual Meeting, set for Dec. 9-12 ... Read more

November 9, 2017November 9, 2017

Seattle Genetics Asks FDA to Accept Adcetris as Treatment for Hodgkin’s Lymphoma

News

Seattle Genetics has asked the U.S. Food and Drug Administration (FDA) to expand the label for Adcetris (brentuximab vedotin) to be used in combination with chemotherapy as a first-line treatment ... Read more

June 29, 2017June 29, 2017

Adcetris-Chemotherapy Combo Lengthens the Time for Hodgkin’s Lymphoma to Progress, Trial Shows

News

Adding Adcetris (brentuximab vedotin) to standard chemotherapy significantly lengthens the time it takes for Hodgkin’s lymphoma to progress, or for a patient to die, according to an updated of Phase 3 clinical ... Read more